The first in a new class of drug for treating chronic obstructive pulmonary disease has been launched in the UK.
Roflumilast (Daxas) is the first orally administered selective phosphodiesterase 4 (PDE4) inhibitor to be licensed for COPD.
It is indicated for maintenance treatment of severe COPD - FEV1 post-bronchodilator less than 50 per cent predicted - associated with chronic bronchitis in adult patients with a history of frequent exacerbations as an add on to bronchodilator treatment.
Nursing Times Learning
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Click on the topics below to get started: